IL257755A - Modulation of lgals3bp to treat systemic lupus erythematosus - Google Patents

Modulation of lgals3bp to treat systemic lupus erythematosus

Info

Publication number
IL257755A
IL257755A IL257755A IL25775518A IL257755A IL 257755 A IL257755 A IL 257755A IL 257755 A IL257755 A IL 257755A IL 25775518 A IL25775518 A IL 25775518A IL 257755 A IL257755 A IL 257755A
Authority
IL
Israel
Prior art keywords
lgals3bp
modulation
lupus erythematosus
systemic lupus
treat systemic
Prior art date
Application number
IL257755A
Other languages
English (en)
Hebrew (he)
Inventor
Julie Demartino
Jonathan Derry
Jaromir Vlach
Nuruddeen Lewis
Melinda Genest
Shinji Okitsu
Original Assignee
Merck Patent Gmbh
Julie Demartino
Jonathan Derry
Jaromir Vlach
Nuruddeen Lewis
Melinda Genest
Shinji Okitsu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh, Julie Demartino, Jonathan Derry, Jaromir Vlach, Nuruddeen Lewis, Melinda Genest, Shinji Okitsu filed Critical Merck Patent Gmbh
Publication of IL257755A publication Critical patent/IL257755A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL257755A 2015-08-31 2018-02-27 Modulation of lgals3bp to treat systemic lupus erythematosus IL257755A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562212163P 2015-08-31 2015-08-31
PCT/US2016/049378 WO2017040464A1 (en) 2015-08-31 2016-08-30 Methods for the modulation of lgals3bp to treat systemic lupus erythematosus

Publications (1)

Publication Number Publication Date
IL257755A true IL257755A (en) 2018-04-30

Family

ID=56883878

Family Applications (1)

Application Number Title Priority Date Filing Date
IL257755A IL257755A (en) 2015-08-31 2018-02-27 Modulation of lgals3bp to treat systemic lupus erythematosus

Country Status (9)

Country Link
US (1) US20180251559A1 (enExample)
EP (1) EP3344283A1 (enExample)
JP (2) JP2018526443A (enExample)
CN (1) CN107921112A (enExample)
AU (1) AU2016317768A1 (enExample)
CA (1) CA2994180A1 (enExample)
HK (1) HK1252815A1 (enExample)
IL (1) IL257755A (enExample)
WO (1) WO2017040464A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018156448A1 (en) * 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity
KR101946884B1 (ko) * 2017-04-25 2019-02-13 고려대학교 산학협력단 대사체 분석을 이용한 베체트병의 진단방법
EP4174086A4 (en) * 2020-06-30 2024-07-24 The Asan Foundation ANTIBODIES SPECIFICALLY BINDING TO LGALS3BP AND USE THEREOF
KR102704018B1 (ko) * 2020-06-30 2024-09-06 재단법인 아산사회복지재단 Lgals3bp에 특이적으로 결합하는 항체 및 이의 용도
KR20230160803A (ko) 2021-03-24 2023-11-24 에이지씨 가부시키가이샤 축전 디바이스 전극용 프라이머, 프라이머층 형성용의 조성물, 축전 디바이스용 전극 및 이차 전지
WO2025075163A1 (ja) * 2023-10-04 2025-04-10 国立大学法人東北大学 自己反応性ｄｎ２ｂ細胞が産生する自己抗体およびその使用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200001247T2 (tr) * 1997-01-10 2002-06-21 Biogen Inc. Anti-CD40L bileşikleri ile lupus nefritis tedavisi.
CA2470763A1 (en) * 2001-12-18 2003-06-26 Mondobiotech Laboratories Anstalt Novel pharmaceutical composition of interferon gamma or pirfenidone with molecular diagnostics for the improved treatment of interstitial lung diseases
US8163896B1 (en) * 2002-11-14 2012-04-24 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
ES2244270A1 (es) * 2003-01-31 2005-12-01 Pilar Universidad Autonoma De Madrid Nueva estrategia de regulacion inmune fundamentada en la molecula inducible durante la activacion leucocitaria cd69.
WO2004076682A2 (en) * 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
EP2566878A4 (en) * 2010-03-26 2013-10-23 Jolla Inst Allergy Immunolog METHOD OF INHIBITING INFLAMMATORY AND INFLAMMATORY DISEASES BY GAL-3BP (BTBD17B, LGALS3BP, GALECTIN-3 BINDING PROTEIN, MAC-2 BINDING PROTEIN)
JP2013527834A (ja) * 2010-03-29 2013-07-04 マサチューセッツ インスティテュート オブ テクノロジー 抗炎症因子
EP2646826A1 (en) * 2010-11-30 2013-10-09 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patienten Zorg Method for prognosticating the clinical response of a patient to b-lymphocyte inhibiting or depleting therapy in interferon driven diseases such as sle

Also Published As

Publication number Publication date
JP2021050217A (ja) 2021-04-01
CN107921112A (zh) 2018-04-17
WO2017040464A1 (en) 2017-03-09
HK1252815A1 (zh) 2019-06-06
EP3344283A1 (en) 2018-07-11
CA2994180A1 (en) 2017-03-09
AU2016317768A1 (en) 2018-02-22
JP2018526443A (ja) 2018-09-13
US20180251559A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
IL259421B (en) ror - gamma modulators
GB2558826B (en) Mitigation of anti-sandbox malware techniques
IL243006B (en) Real-time delay beam stabilization techniques are optimized for immediate bandwidth improvement
HUE044083T2 (hu) Alvivõk újracstornázása
IL257026A (en) Solid state forms of eluxadoline
IL257755A (en) Modulation of lgals3bp to treat systemic lupus erythematosus
GB2536295B (en) Forming of battery components
GB201521536D0 (en) Apparatus for the mnufacture of battery components
SI3845221T1 (sl) Trdne oblike sofosbuvirja
GB2536059B (en) Secure control of insecure device
EP3149603A4 (en) Customized configuration of cloud-based applications prior to deployment
HUE048433T2 (hu) Tökéletesítés kábeltálcák szakaszaihoz
IL246979A0 (en) Crystalline forms of sofosbuvir
ZA201706282B (en) Solid forms of menaquinols
GB201418395D0 (en) Cyclo-depolymerisation of polybutadiene
GB2543602B (en) Mitigation of anti-sandbox malware techniques
SG11201706327PA (en) Heteroatom containing modified diene polymers
PL2960883T3 (pl) Określanie co najmniej jednej cechy pojazdu
IL246959A0 (en) Ion channel modulator solid forms
GB2550525B (en) Forming of battery components
GB201600964D0 (en) Determination of vehicle capabilities
GB2532702B (en) The determination of the characteristics of magnets
SG11201607445QA (en) Methods of modulating wars2
TWM490377U (en) Improved structure of C clamp
GB201407975D0 (en) Stabilization of the spine